GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ajanta Pharma Ltd (NSE:AJANTPHARM) » Definitions » EV-to-EBITDA

Ajanta Pharma (NSE:AJANTPHARM) EV-to-EBITDA : 23.47 (As of May. 06, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Ajanta Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ajanta Pharma's enterprise value is ₹294,858 Mil. Ajanta Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₹12,565 Mil. Therefore, Ajanta Pharma's EV-to-EBITDA for today is 23.47.

The historical rank and industry rank for Ajanta Pharma's EV-to-EBITDA or its related term are showing as below:

NSE:AJANTPHARM' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.73   Med: 17.45   Max: 60.44
Current: 23.47

During the past 13 years, the highest EV-to-EBITDA of Ajanta Pharma was 60.44. The lowest was 11.73. And the median was 17.45.

NSE:AJANTPHARM's EV-to-EBITDA is ranked worse than
76.17% of 705 companies
in the Drug Manufacturers industry
Industry Median: 14.53 vs NSE:AJANTPHARM: 23.47

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-06), Ajanta Pharma's stock price is ₹2383.85. Ajanta Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹64.790. Therefore, Ajanta Pharma's PE Ratio for today is 36.79.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Ajanta Pharma EV-to-EBITDA Historical Data

The historical data trend for Ajanta Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ajanta Pharma EV-to-EBITDA Chart

Ajanta Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.20 14.81 14.50 16.45 22.07

Ajanta Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.45 19.99 22.11 23.25 22.07

Competitive Comparison of Ajanta Pharma's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Ajanta Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ajanta Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ajanta Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ajanta Pharma's EV-to-EBITDA falls into.



Ajanta Pharma EV-to-EBITDA Calculation

Ajanta Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=294858.289/12565.4
=23.47

Ajanta Pharma's current Enterprise Value is ₹294,858 Mil.
Ajanta Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹12,565 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ajanta Pharma  (NSE:AJANTPHARM) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Ajanta Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2383.85/64.790
=36.79

Ajanta Pharma's share price for today is ₹2383.85.
Ajanta Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹64.790.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Ajanta Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ajanta Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ajanta Pharma (NSE:AJANTPHARM) Business Description

Traded in Other Exchanges
Address
Ajanta House, 98 Government Industrial Area, Charkop, Kandivli (West), Mumbai, MH, IND, 400 067
Ajanta Pharma Ltd is a drug manufacturing company with a focus on specialty pharmaceutical products. The company maintains a global presence while generating the vast majority of its revenue in Africa and India. Ajanta's strategy aims to successfully select molecules and products for development while enhancing its research and development capabilities. The company works to develop formulations in different dosages such as tablets, cream, capsules, liquid, and lotion. The company's manufacturing plants are located in India.

Ajanta Pharma (NSE:AJANTPHARM) Headlines

No Headlines